BU-NOT-SET

CONTACT US
The QbD approach: Key advantages in clinical and commercial phases
  • Analytical chemistry
Lab
Insight
Sustainability report 2020
  • Sustainability
Report
Report
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
  • Drug substance
Man at poster
Poster
Recipharm Analytical Solutions™
  • Analytical chemistry
Icon
Fact sheet
Impurity identification
  • Analytical chemistry
Woman inserting vials in machine
Fact sheet
Stability studies
  • Analytical chemistry
hand holding vials plate
Fact sheet
Extractables & leachables testing
  • Analytical chemistry
Product mix
Fact sheet
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
  • Industry trends
Eyes
Insight
Global expansion in the CDMO field
  • Industry trends
Eyes
Insight
Insight
  • Industry trends
A CDMO’s insight into the pharma M&A landscape
Insight
  • Industry trends
Recipharm’s continuous global support throughout the COVID-19 pandemic
Insight
  • Manufacturing
Is outsourcing the most viable pathway for innovators?
Case study
  • Drug product
Developing a generic prolonged-release isosorbide-5-mononitrate tablet
Insight
  • Industry trends
Recipharm Wins two 2020 CMO Leadership Awards
Insight
  • Corporate
Recipharm’s global teams support and engage with their local communities in the fight against COVID-19
Insight
  • Manufacturing
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
Brochure
  • Corporate
Recipharm 25 years
Fact sheet
  • Drug substance
API product list